The estimated Net Worth of Stephen P Squinto is at least $42.1 million dollars as of 27 April 2021. Stephen Squinto owns over 19,432 units of SpringWorks Therapeutics stock worth over $4,860,644 and over the last 21 years he sold SWTX stock worth over $36,844,791. In addition, he makes $444,068 as Acting Head of Research and Development et Director at SpringWorks Therapeutics.
Stephen has made over 78 trades of the SpringWorks Therapeutics stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 19,432 units of SWTX stock worth $1,480,524 on 27 April 2021.
The largest trade he's ever made was buying 275,000 units of SpringWorks Therapeutics stock on 17 September 2019 worth over $4,950,000. On average, Stephen trades about 13,038 units every 61 days since 2003. As of 27 April 2021 he still owns at least 125,728 units of SpringWorks Therapeutics stock.
You can see the complete history of Stephen Squinto stock trades at the bottom of the page.
Dr. Stephen P. Squinto Ph.D. serves as Acting Head of Research and Development, Director of the Company. Dr. Squinto has been an Executive Partner at OrbiMed Advisors LLC since January 2015. Previously, Dr. Squinto co-founded Alexion Pharmaceuticals, Inc. and served as its Executive Vice President and Chief Global Operations Officer from 2012 to January 2015 and as its Global Head of Research and Development from 2007 to 2012. Dr. Squinto has served as Acting Head of Research and Development of Passage Bio, Inc. since January 2020, and prior to that served as interim Chief Executive Officer of Passage Bio from September 2018 to January 2020. Dr. Squinto also has served as a member of Passage’s board of directors since September 2018. Dr. Squinto also previously served as a member of the board of directors of Arvinas, Inc. from October 2015 to September 2018 and Audentes Therapeutics, Inc. from April 2015 to January 2018. Dr. Squinto holds a Ph.D. in biochemistry and biophysics and a B.A. in chemistry from Loyola University of Chicago. Squinto is qualified to serve on our Board of Directors based on his experience in the biopharmaceutical industry, including his operational experience in drug discovery and development.
As the Acting Head of Research and Development et Director of SpringWorks Therapeutics, the total compensation of Stephen Squinto at SpringWorks Therapeutics is $444,068. There are 10 executives at SpringWorks Therapeutics getting paid more, with Saqib Islam having the highest compensation of $3,284,920.
Stephen Squinto is 63, he's been the Acting Head of Research and Development et Director of SpringWorks Therapeutics since 2017. There are 3 older and 15 younger executives at SpringWorks Therapeutics. The oldest executive at SpringWorks Therapeutics, Inc. is Freda Lewis-Hall, 65, who is the Independent Director.
Stephen's mailing address filed with the SEC is C/O SPRINGWORKS THERAPEUTICS, INC.,, 100 WASHINGTON BLVD., STAMFORD,, CT, 06902.
Over the last 6 years, insiders at SpringWorks Therapeutics have traded over $386,249,433 worth of SpringWorks Therapeutics stock and bought 800,000 units worth $14,400,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Capital Life Sciences Inves... et Jeffrey Lawrence Schwartz. On average, SpringWorks Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $6,795,384. The most recent stock trade was executed by Saqib Islam on 3 September 2024, trading 49,000 units of SWTX stock currently worth $1,987,930.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
SpringWorks Therapeutics executives and other stock owners filed with the SEC include: